Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
C-type Natriuretic Peptide (CNP)
Overview
C-type natriuretic peptide is a 22-amino acid member of the natriuretic peptide family that selectively activates natriuretic peptide receptor B (NPR-B). Unlike ANP and BNP, CNP is produced primarily in vascular endothelium and functions as a paracrine regulator of vascular tone and endothelial permeability with minimal direct renal effects.
Mechanism of Action
CNP also plays important roles in bone growth and chondrocyte proliferation through cyclic GMP signaling.
Research Summary & Key Findings
Vosoritide, an analogue of CNP, received FDA approval in 2021 for achondroplasia based on the phase 3 trial showing increased growth velocity in pediatric patients (NEJM, 2020). Cardiovascular applications of CNP remain investigational, with preclinical studies demonstrating anti-fibrotic and anti-remodeling properties in models of vascular and cardiac disease.
Clinical Status
C-type Natriuretic Peptide (CNP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "C-type Natriuretic Peptide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "C-type Natriuretic Peptide"
Registered interventional and observational studies, including status and phase.
- PubChem: "C-type Natriuretic Peptide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cardiovascular
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the south...
View detailsNesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular ...
View detailsAngiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Ang...
View detailsSerelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked ...
View detailsNo lawful pathway today
C-type Natriuretic Peptide (CNP) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.